News

AFFiRiS announced a realignment of its development strategy on neurodegenerative diseases, a core area of expertise of the company. Affiris will now...

21 Jan'20

The wait has come to an end – the Phenaris Transporter Models are officially available for purchase! These computational models can predict...

17 Jan'20

Scientists from the labs of Alipasha Vaziri at The Rockefeller University and the Research Institute of Molecular Pathology (IMP), together with...

14 Jan'20

Valneva announced today that the U.S. government Department of Defense (DoD) has exercised an option to purchase 80,000 additional doses of its...

13 Jan'20

Vienna Drosophila Resource Center's contribution to the genome research worldwide has been acknowledged in the Austria-wide newspaper Die Presse.

09 Jan'20

Valneva today announced a further expansion of its global commercial infrastructure with the opening of a French commercial office in Lyon.

08 Jan'20

Valneva announced today that an End Of Phase 2 meeting has been scheduled with the U.S. Food and Drug Administration on February 24, 2020 for its...

20 Dec'19

Max Perutz Labs group leader Shotaro Otsuka was awarded a “Life Science” grant by the Vienna Science and Technology Fund (WWTF). This project is a...

20 Dec'19

Researchers from IMBA – Institute of Molecular Biotechnology of the Austrian Academy of Sciences – are granted funding for two projects from the...

20 Dec'19

Valneva SE confirmed today that it has completed the delisting of its ordinary and preferred shares from the Vienna Stock Exchange (“VSE”). Valneva...

18 Dec'19

Phenaris announced another big success accomplished with ToxPHACTS shortly before the end of the year, as they won won the 3rd place at the i2b...

17 Dec'19

All organisms need to adjust their energy consumption in response to internal and external signals, thereby allocating energy to growth, reproduction...

AFFiRiS announces Phase 2 study in Parkinson's and new focus on neurodegenerative diseases

Phenaris launches Transporter Models

How decisions unfold in a zebrafish brain

Valneva: US DoD Exercises Option on IXIARO® Supply Contract Bringing Total Value to $70 Million

VBCF core facility VDRC in "Die Presse"

Valneva Expands its Commercial Operations with the Opening of its French Commercial Office

Valneva Announces End of Phase 2 Meeting with the FDA for its Chikungunya Vaccine Candidate

How to pack your genetic suitcase – WWTF grant on chromosome folding awarded

Two grants on imaging projects go to IMBA

Valneva Completes Delisting from the Vienna Stock Exchange

Phenaris wins 3rd place at i2b Businessplan Competition

Moonstruck worms: how lunar cycles affect metabolic decisions